We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

5 hedge funds and large institutions have $758K invested in Phio Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

75% more capital inflows, than outflows

Capital inflows: $1.09M | Capital outflows: $624K

67% more funds holding

Funds holding: 3 → 5 (+2)

2.34% more ownership

Funds ownership: 9.82% → 12.17% (+2.3%)

Holders
5
Holders Change
+2
Holders Change %
+66.67%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$547K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$313K
3
Goldman Sachs
Goldman Sachs
New York
+$78.2K
4
Renaissance Technologies
Renaissance Technologies
New York
+$78.2K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$78.2K

Top Sellers

Rank Fund Capital Flow
1
Broadfin Capital
Broadfin Capital
New York
-$585K
2
Citadel Advisors
Citadel Advisors
Florida
-$22K
3
UBS Group
UBS Group
Switzerland
-$16K
4
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$1K

PHIO Hedge Fund Activity: Q4 2016 in Review

5 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2016, worth a combined $758K — down 37% from $1.19M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new PHIO positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $547K. The largest seller was Broadfin Capital, exiting entirely with an estimated $585K sold.

  • 5 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2016, up from 3 in Q3 2016.
  • Funds reported $758K of Phio Pharmaceuticals stock for Q4 2016, down 37% quarter-over-quarter.
  • 3 funds opened new Phio Pharmaceuticals positions in Q4 2016 and 1 closed out, a net change of +2 holders.
  • The largest Phio Pharmaceuticals buyer in Q4 2016 was Sabby Management, an estimated $547K added.
  • The largest Phio Pharmaceuticals seller in Q4 2016 was Broadfin Capital, an estimated $585K sold.

Based on aggregated 13F filings for Q4 2016.